Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06345066 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3841136 in Overweight and Obese Participants
A Phase 1 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 96
- Enrollment target
- 3
- Study locations
NCT06345066: Completed Phase 1 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
NCT06345066 is a Phase 1 study of Obesity and Overweight that has completed, run by Eli Lilly and Company. The registered enrollment target is 96 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (88% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06345066, a Phase 1 study of Obesity and Overweight, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 96 participants
- Enrollment target
- 3
- Study locations
Study Summary
The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.
Primary Outcome
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
- DRUG LY3841136
Study Locations (3)
Florida
- Fortrea Clinical Research Unit - Daytona Beach
Texas
- Fortrea Clinical Research Unit - Dallas
Wisconsin
- Fortrea Clinical Research Unit - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2024-04-03 |
| Est. Completion | 2025-09-29 |
| Phase | Phase 1 |
What the finished NCT06345066 record still lists
NCT06345066 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (88% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06345066 reports a single indexed study location in Florida, Texas, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06345066 about?
NCT06345066 is a clinical study titled "A Study of LY3841136 in Overweight and Obese Participants". The main purpose of this study is to assess the safety and tolerability of LY3841136 when administered in combination with tirzepatide in overweight and obese patients. The study will last up to approximately 42 weeks.
What is the current status of trial NCT06345066?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 96 participants. The study started on 2024-04-03. Estimated completion is 2025-09-29.
What conditions does trial NCT06345066 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT06345066?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG), LY3841136 (DRUG).
Who is sponsoring clinical trial NCT06345066?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06345066 being conducted?
This trial has 3 study locations across Florida, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06345066's enrollment target sits among peer trials
96 504th of 1053 higher than 545 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI